FDA's Opioid REMS Proposal
This article was originally published in RPM Report
Executive Summary
Here is the proposed class-wide REMS developed by FDA and presented to the advisory committee.
You may also be interested in...
Controlling Opioids: REMS Meets Congressional Resistance
The Food & Drug Administration’s work on curbing abuse of long-acting opioids hasn’t lacked for outreach. The three-year long effort to develop a formal Risk Evaluation & Mitigation Strategy to help ensure appropriate use of products like Purdue Pharma’s OxyContin has involved input from two dozen different manufacturers, formal presentations by more than 75 outside stakeholder groups, and literally hundreds of public comments.
Opioid REMS: Committee Rejects FDA Proposal, But Sponsors Should Embrace It
The combined Anesthetic & Life Support Drugs and Drug Safety & Risk Management advisory committees voted strongly (25-10) against FDA’s proposed classwide educational REMS for long-acting opioids; but the vote does not stop the process. In fact, FDA may have achieved much of what it set out to do by just by proposing a class REMS in the area.
Pediatric Disincentive? Implications Of US Pricing Bill
The ripple effects from the pending drug price reform legislation in the US would include fundamentally changing the math on the incentive to encourage pediatric research on new products.